Travere Therapeutics, Inc.

Travere Therapeutics reported total revenue of $490.7 million for FY 2025, with a net loss of $25.5 million. The company generated positive operating cash flow of $37.8 million from continuing operations, driven by strong revenue performance and effective working capital management. Key financial highlights include an operating loss of $62.8 million, partially offset by other income of $13.6 million. The balance sheet shows total assets of $605.2 million, with cash and cash equivalents of $93.0 million and marketable debt securities of $229.8 million. Total liabilities stand at $490.4 million, including convertible debt of $311.7 million, resulting in stockholders' equity of $114.8 million. The company's comprehensive loss was $26.7 million for the period.

Key Takeaways